OverviewSuggest Edit

Kadmon is a biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology, and genetic diseases. 

TypePublic
Founded2010
HQNew York, US
Websitekadmon.com
Employee Ratings2.1

Latest Updates

Employees (est.) (Dec 2018)116(+15%)
Revenue (FY, 2018)$1.4 M(-88%)
Share Price (Jun 2019)$2

Key People/Management at Kadmon

Harlan Waksal

Harlan Waksal

President and Chief Executive Officer
Steven Gordon

Steven Gordon

Executive Vice President, General Counsel, Chief Administrative, Compliance and Legal Officer
John Ryan

John Ryan

Executive Vice President, Chief Medical Officer
Show more

Kadmon Office Locations

Kadmon has an office in New York
New York, US (HQ)
450 E 29th St
Show all (1)

Kadmon Financials and Metrics

Kadmon Revenue

Embed Graph
View revenue for all periods
Kadmon's revenue was reported to be $1.40 m in FY, 2018
USD

Revenue (Q2, 2019)

226.0k

Gross profit (Q2, 2019)

181.0k

Gross profit margin (Q2, 2019), %

80.1%

Net income (Q2, 2019)

9.2m

EBIT (Q2, 2019)

(24.8m)

Market capitalization (10-Jun-2019)

252.5m

Closing stock price (10-Jun-2019)

2.0

Cash (30-Jun-2019)

86.2m
Kadmon's current market capitalization is $252.5 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

26.1m12.3m1.4m

Cost of goods sold

3.5m1.3m412.0k

Gross profit

22.6m10.9m984.0k

Gross profit Margin, %

87%89%70%
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

6.4m5.7m5.6m3.0m2.3m433.0k359.0k372.0k241.0k226.0k

Cost of goods sold

880.0k880.0k567.0k266.0k277.0k199.0k103.0k59.0k31.0k45.0k

Gross profit

5.5m4.8m5.0m2.7m2.0m234.0k256.0k313.0k210.0k181.0k

Gross profit Margin, %

86%85%90%91%88%54%71%84%87%80%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

36.1m67.5m94.7m

Accounts Receivable

655.0k325.0k1.7m

Inventories

2.0m201.0k925.0k

Current Assets

40.3m70.0m98.9m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(208.8m)(79.8m)(54.3m)

Inventories

1.1m95.0k(994.0k)

Accounts Payable

530.0k1.6m2.0m

Cash From Operating Activities

(52.9m)(64.1m)(71.2m)
USDY, 2019

Financial Leverage

1.5 x
Show all financial metrics

Kadmon Online and Social Media Presence

Embed Graph

Kadmon News and Updates

Kadmon Announces Appointment of Steven Meehan as CFO

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Steven Meehan as Executive Vice President, Chief Financial Officer. Mr. Meehan, who has served as a member of the Board of Directors at Kadmon since 2017, has over 25 years of financia…

Kadmon Announces Appointment of Cynthia Schwalm to Board of Directors

NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced the appointment of Cynthia Schwalm to its Board of Directors. Ms. Schwalm has extensive pharmaceutical industry experience, having held management roles at Johnson & Johnson, Amgen and Eisai, and mos…

Kadmon Announces Appointment of Tasos G. Konidaris as Interim Chairman of the Board

NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Tasos G. Konidaris, a member of Kadmon’s board of directors, has been appointed interim chairman, effective immediately. Mr. Konidaris has significant experience in the biotechnology industry, inclu…

Kadmon Chairman Bart M. Schwartz to Step Down from Board

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Bart M. Schwartz, Esq. is stepping down as director and Chairman of the Board of Directors (the “Board”) due to increasing responsibilities at his charitable commitments, including at the All Stars …

Kadmon Provides Business Update and Reports Third Quarter 2018 Financial Results

NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the third quarter of 2018.

Kadmon to Present at the Jefferies 2018 London Healthcare Conference

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14 at 8:40 a.m. GMT (3:40 a.m. ET).
Show more

Kadmon Frequently Asked Questions

  • When was Kadmon founded?

    Kadmon was founded in 2010.

  • Who are Kadmon key executives?

    Kadmon's key executives are Harlan Waksal, Steven Gordon and John Ryan.

  • How many employees does Kadmon have?

    Kadmon has 116 employees.

  • What is Kadmon revenue?

    Latest Kadmon annual revenue is $1.4 m.

  • What is Kadmon revenue per employee?

    Latest Kadmon revenue per employee is $12 k.

  • Who are Kadmon competitors?

    Competitors of Kadmon include Biogen, Athersys and Reata Pharmaceuticals.

  • Where is Kadmon headquarters?

    Kadmon headquarters is located at 450 E 29th St, New York.

  • Where are Kadmon offices?

    Kadmon has an office in New York.

  • How many offices does Kadmon have?

    Kadmon has 1 office.